Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2000 1
2001 1
2004 3
2005 2
2006 3
2008 7
2009 13
2010 8
2011 8
2012 8
2013 4
2014 1
2015 5
2016 7
2017 5
2018 2
2019 4
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

79 results
Results by year
Filters applied: . Clear all
Page 1
Driving CAR T-cells forward.
Jackson HJ, Rafiq S, Brentjens RJ. Jackson HJ, et al. Nat Rev Clin Oncol. 2016 Jun;13(6):370-83. doi: 10.1038/nrclinonc.2016.36. Epub 2016 Mar 22. Nat Rev Clin Oncol. 2016. PMID: 27000958 Free PMC article. Review.
Therapeutic T cell engineering.
Sadelain M, Rivière I, Riddell S. Sadelain M, et al. Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Nature. 2017. PMID: 28541315 Free PMC article. Review.
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ. Smith EL, et al. Sci Transl Med. 2019 Mar 27;11(485):eaau7746. doi: 10.1126/scitranslmed.aau7746. Sci Transl Med. 2019. PMID: 30918115 Free PMC article.
The basic principles of chimeric antigen receptor design.
Sadelain M, Brentjens R, Rivière I. Sadelain M, et al. Cancer Discov. 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2. Cancer Discov. 2013. PMID: 23550147 Free PMC article. Review.
Novel immunotherapies in lymphoid malignancies.
Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Batlevi CL, et al. Nat Rev Clin Oncol. 2016 Jan;13(1):25-40. doi: 10.1038/nrclinonc.2015.187. Epub 2015 Nov 3. Nat Rev Clin Oncol. 2016. PMID: 26525683 Free PMC article. Review.
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Brentjens RJ, et al. Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17. Blood. 2011. PMID: 21849486 Free PMC article. Clinical Trial.
79 results